<DOC>
	<DOCNO>NCT00836043</DOCNO>
	<brief_summary>This study collect data safety , effectiveness patient acceptance MabCampath treatment daily life condition .</brief_summary>
	<brief_title>Safety , Effectiveness Patient Acceptance Treatment With MabCampath Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>As 29 May 2009 , clinical trial sponsor Genzyme Corporation . NOTE : This study originally post sponsor Schering AG , Germany , subsequently rename Bayer Schering Pharma AG , Germany .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>In outpatient suffer CLL , treat Mab Campath , routinely monitor PCR ( Polymerase Chain Reaction ) CMV infection MabCampath treatment least 2 month follow completion treatment . In accordance Summaries Product Characteristics ( SPC ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>CLL</keyword>
	<keyword>alemtuzumab</keyword>
</DOC>